Research & Development
R&D
We continuously develop innovative technologies to create products and solutions optimized for cell processing and clinical research.
Medical and Life Science Equipment Development Roadmap
Development of cell and exosome processing platforms leveraging advanced stem cell technology
Tissue Preprocessing System
​
  • Designed for Efficient Preprocessing of Animal and Human Tissues
Cell Separation System
​
  • Isolation of Cells from Tissue 
  • / For Clinical Research
​


소닉스템.png

소닉스템키트.png

Exosomes
​
  • Large-Scale Production of Exosomes
  • For Cosmetic Ingredients and Clinical Research

소니엑소_로고.png

엑소컬처.png

Laboratory Equipment
​
  • Mini Clean Benches,
  • Cell Thawing Devices,
  • and More Development of Equipment for Cell Processing and Laboratory Applications
​​
미니클린랩.png
Harnessing Cellabsys’ platform technologies
       —ultrasound-based cell separation, culture, exosome production & isolation, and tissue preprocessing—
                                                             to maximize cell productivity and efficacy. 
        Driving the development of global-standard cell processing platforms and next-generation cell therapies.
Research Activities
002-1.png


Large-Scale Production of Stem Cells and Exosomes
​
Cellabsys Inc. applies stem cell-optimized culture environment technologies to enable the large-scale production of high-purity stem cell lines and exosomes.
001.png


Specialized Exosome Production Technology
​
Cellabsys’ proprietary technology enables the production of drug-loaded exosomes by efficiently incorporating specific therapeutic agents into exosomes.
003.png

Clinical Research
  1. Clinical studies using SVF are expanding across various diseases.
  2. The highest-quality SVF can be utilized in clinical research through enzyme-free SVF isolation.
  3. We strive to advance treatments for various intractable diseases using low-risk cell therapies in cutting-edge regenerative medicine.
Preclinical Study Results 
Angiogenic Effects of SVF
그림1.gif
A single subcutaneous administration of SVF (2×10⁵ cells/head) and SVF+HA (2×10⁵ cells/head) in BALB/c nude mice showed a trend toward increased CD31 expression, suggesting a potential effect on angiogenesis.
Achievements
엑소컬쳐.jpg
엑소컬쳐 출원
소니엑소_특허등록_2506.jpg
소니엑소 특허등록
상표_소닉스템_10류.jpg
소닉스템 상표등록
소니스킨-특허등록.jpg
소니스킨 특허등록
특허_소닉스템_출원.jpg
소닉스템 특허결정 2025
미국_특허출원-2.jpg
미국 특허출원
미국_특허출원-1.jpg
미국 특허출원
소니엑소_상표9류_출원사실증명원-1.jpg
소니엑소
상표9류 특허출원
소니엑소_상표10류_출원사실증명원-1.jpg
소니엑소
상표10류 특허출원
소니스킨_상표9류_출원사실증명원-1.jpg
소니스킨
상표9류 특허출원
소니스킨_상표10류_출원사실증명원-1.jpg
소니스킨
상표10류 특허출원
벤처기업확인서-셀랩시스.jpg
벤처기업확인서
수상_증비_결과공문__은상수상.jpg
수상내역-은상
수상확인증_(주)셀랩시스.jpg
수상내역-최우수상
우수상_수상.jpg
수상내역-우수상